Anti-CD20-based therapy of B cell lymphoma: state of the art

被引：52

作者：

Kosmas, C

Stamatopoulos, K

Stavroyianni, N

Tsavaris, N

Papadaki, T

机构：

[1] Metaxa Canc Hosp, Div Med Oncol 2, Dept Med, Piraeus, Greece

[2] G Papanicolaou Gen Hosp, Dept Hematol, Thessaloniki, Greece

[3] Univ Athens, Sch Med, Dept Pathophysiol, Oncol Unit,Laikon Gen Hosp, GR-11527 Athens, Greece

[4] Evangelismos Med Ctr, Hemopathol Dept, Athens, Greece

来源：

LEUKEMIA | 2002年 / 16卷 / 10期

关键词：

monoclonal antibodies; B cell lymphoma; rituximab; tositumomab; ibritumomab;

D O I：

10.1038/sj.leu.2402639

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Over the last 5 years, studies applying the chimeric anti-CD20 MAb have renewed enthusiasm and triggered world-wide application of anti-CD20 MAb-based therapies in B cell non-Hodgkin's lymphoma (NHL). Native chimeric anti-CD20 and isotope-labeled murine anti-CD20 MAbs are currently employed with encouraging results as monotherapy or in combination with conventional chemotherapy and in consolidation of remission after treatments with curative intent (ie after/ in combination with high-dose chemotherapy and hematopoietic stem cell rescue). On the available experience, anti-CD20 MAb-based therapeutic strategies will be increasingly integrated in the treatment of B cell NHL and related malignancies.

引用

页码：2004 / 2015

页数：12

共 112 条

[61] Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma [J].

Khouri, IF ;

Romaguera, J ;

Kantarjian, H ;

Palmer, JL ;

Pugh, WC ;

Korbling, M ;

Hagemeister, F ;

Samuels, B ;

Rodriguez, A ;

Giralt, S ;

Younes, A ;

Przepiorka, D ;

Claxton, D ;

Cabanillas, F ;

Champlin, R .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (12) :3803-3809

[62]

Kimby E, 2000, BLOOD, V96, p577A

[63] CONTINUOUS CULTURES OF FUSED CELLS SECRETING ANTIBODY OF PREDEFINED SPECIFICITY [J].

KOHLER, G ;

MILSTEIN, C .

NATURE, 1975, 256 (5517) :495-497

[64]

KOSMAS C, 1992, CANCER RES, V52, P904

[65]

KOSMAS C, 1995, J NUCL MED, V36, P746

[66] CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation [J].

Kuehnie, I ;

Huls, MH ;

Liu, ZS ;

Semmelmann, M ;

Krance, RA ;

Brenner, MK ;

Rooney, CM ;

Heslop, HE .

BLOOD, 2000, 95 (04) :1502-1505

[67] Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma [J].

Ladetto, M ;

Zallio, F ;

Vallet, S ;

Ricca, I ;

Cuttica, A ;

Caracciolo, D ;

Corradini, P ;

Astolfi, M ;

Sametti, S ;

Volpato, F ;

Bondesan, P ;

Vitolo, U ;

Boccadoro, M ;

Pileri, A ;

Gianni, AM ;

Tarella, C .

LEUKEMIA, 2001, 15 (12) :1941-1949

[68]

Lauria F, 2001, HAEMATOLOGICA, V86, P1046

[69] A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma [J].

Lazzarino, M ;

Arcaini, L ;

Bernasconi, P ;

Alessandrino, EP ;

Gargantini, L ;

Cairoli, R ;

Orlandi, E ;

Astori, C ;

Brusamolino, E ;

Pagnucco, G ;

Colombo, AA ;

Calatroni, S ;

Iacona, I ;

Regazzi, MB ;

Morra, E .

BRITISH JOURNAL OF HAEMATOLOGY, 2002, 116 (01) :229-235

[70]

Leonard JP, 2001, BLOOD, V98, p844A

← 2 3 4 5 6 7 8 9 10 11 →